Clinical Trials Logo

Metastatic Urothelial Carcinoma clinical trials

View clinical trials related to Metastatic Urothelial Carcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05154994 Suspended - Clinical trials for Metastatic Urothelial Carcinoma

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

RESOLVE
Start date: January 14, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Belinostat is a potential anti-cancer drug, known as a histone deacetylase (HDAC) inhibitor, which means that belinostat stops the activity of HDAC enzymes (an enzyme is a protein that in small amounts can speed up a biological reaction). HDAC enzymes play an important role in cell growth and cell death. Giving durvalumab and belinostat may improve the body's ability to fight cancer.